Showing 1,567 results

Filters Content type: News, Editors' picks, About HIV Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Access to healthcare

Countries and donors should aim for new $90-$90-$90 target on HIV, hepatitis, TB drug prices, study shows

News
27 July 2017
New & experimental HIV treatments

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

Editor's pick
Business Wire
21 July 2017
Finance & funding

An arbitrary benchmark for access to new drugs

Editor's pick
Financial Times
11 July 2017
Pharmaceutical industry

Drug industry to challenge Nice over new cost limits

Editor's pick
BBC Health
10 July 2017
Pharmaceutical industry

Drug Company Back on the Hook for Adulterated HIV Drugs

Editor's pick
Court House News
10 July 2017
Generic medicines

Surprise FDA Approval of Generic Truvada Is a 'Wakeup Call' for Activists

Editor's pick
The Body
7 July 2017
Pharmaceutical industry

Can Merck knock Glaxo off its HIV perch? Maybe so, one analyst says

Editor's pick
Fierce Pharma
6 July 2017
Pharmaceutical industry

Gilead in row with generics manufacturers over HIV drug in Ireland

Editor's pick
Irish Times
6 July 2017
Pharmaceutical industry

Senior MPs urge post-Brexit EU drug regulation deal

Editor's pick
BBC Health
4 July 2017
PrEP

Generic PrEP approved, but not soon available

Editor's pick
Bay Area Reporter
17 June 2017
Pharmaceutical industry

ViiV Healthcare’s Positive Action Europe Programme awards grants to 14 community-based organisations

Editor's pick
ViiV Healthcare
14 June 2017
PrEP policies & guidelines

FDA Approves Generic Truvada for HIV Treatment and PrEP

Editor's pick
Poz
10 June 2017
PrEP

PrEP Stymied in Europe: What's the hold up?

Editor's pick
AVAC
8 June 2017
Drug-resistant TB

We had to run our own trial for TB drugs – nobody else was doing it

Editor's pick
The Guardian
2 June 2017
Pharmaceutical industry

Gilead and GSK go head-to-head with similar HIV drug data

Editor's pick
Reuters
31 May 2017
Generic medicines

Unexpected side effects with generic abacavir – and potential for rare reactions to other generic ARVs

Editor's pick
HIV i-Base
23 May 2017
Pharmaceutical industry

CHMP recommends for approval generic version of Atripla

Editor's pick
EATG
22 May 2017
Pharmaceutical industry

Gilead's last chronic HIV drug — and what it plans to do now

Editor's pick
San Francisco Business Times
11 May 2017
Health services & systems

Scott Gottlieb wins confirmation as FDA commissioner

Editor's pick
STAT
10 May 2017
PrEP

Gilead slowly rolls out ads for Truvada for PrEP — 4 years after approval

Editor's pick
Medical Marketing & Media
8 May 2017
Pharmaceutical industry

The Corporate Reputation of Pharma Companies, 2016: from the Perspective of 63 HIV/AIDS Patient Groups

Editor's pick
PatientView
8 May 2017
Health services & systems

EMA and heads of national competent authorities discuss consequences of Brexit

Editor's pick
EMA
2 May 2017
People & personal stories

The CEO of HIV

Editor's pick
New York Times
26 April 2017
PrEP

Open letter to Gilead Sciences about PrEP by EATG and the PrEP in Europe Initiative

Editor's pick
EATG / PrEP in Europe
18 April 2017